Last 12 months
Inside the activity.
0 purchase rows · 0 sale rows
Disclosed non-derivative P/S rows, by transaction month. Includes amendments and private transactions.Monthly counts
| Month | Purchases | Sales |
|---|---|---|
| Nov 2025 | 0 | 0 |
| Dec 2025 | 0 | 0 |
| Jan 2026 | 0 | 0 |
| Feb 2026 | 0 | 0 |
| Mar 2026 | 0 | 0 |
| Apr 2026 | 0 | 0 |
| May 2026 | 0 | 0 |
| Jun 2026 | 0 | 0 |
| Jul 2026 | 0 | 0 |
| Aug 2026 | 0 | 0 |
| Sep 2026 | 0 | 0 |
| Oct 2026 | 0 | 0 |
Latest available
Insider transactions
Purchases/sales include open-market and private transactions. Plan disclosure applies to the filing; individual rows may differ. “Not disclosed” is not “unplanned.”
The cutoff filters transaction history only. Company summaries and owner relationships show the latest available disclosures. Parser corrections can improve historical records.
| Transaction date | Owner / reported role | Activity / security | Shares / units | Reported price | Reported value | Details |
|---|---|---|---|---|---|---|
| January 01, 2021 Filed Jan 4, 2021 23:30 UTC |
Kucinski Keith AChief Financial Officer
|
GrantStock option (right to buy) · Derivative | 500,000 | $0.00 Strike: $1.36 | $0.00 |
DisclosureSEC source: 0001493152-21-000132 · ownership.xml · derivative · entry 1 Kucinski Keith A · CIK 0001763405 · Chief Financial Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 500,000 Underlying: Common Stock · 500,000 shares Expires 2030-12-31 F1 · derivative.exercise_date: The option award was made in accordance with the terms of the Issuer's Amended and Restated 2013 Equity Incentive Plan. The option vests as to 25% of the shares on January 1, 2022 with the remaining shares to vest in equal monthly installments over a period of 36 months commencing on February 1, 2022. Read SEC document |
| January 01, 2021 Filed Jan 4, 2021 23:30 UTC |
Ferguson James J. IIIChief Medical Officer
|
GrantStock option (right to buy) · Derivative | 575,000 | $0.00 Strike: $1.36 | $0.00 |
DisclosureSEC source: 0001493152-21-000130 · ownership.xml · derivative · entry 1 Ferguson James J. III · CIK 0001769041 · Chief Medical Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 575,000 Underlying: Common Stock · 575,000 shares Expires 2030-12-31 F1 · derivative.exercise_date: The option award was made in accordance with the terms of the Issuer's Amended and Restated 2013 Equity Incentive Plan. The option vests as to 25% of the shares on January 1, 2022 with the remaining shares to vest in equal monthly installments over a period of 36 months commencing on February 1, 2022. Read SEC document |
| December 31, 2020 Filed Jan 4, 2021 18:30 UTC |
WIKLER MATTHEWDirector
|
GrantCommon Stock | 11,673 | $0.00 | $0.00 |
DisclosureSEC source: 0001493152-21-000131 · ownership.xml · nonDerivative · entry 1 WIKLER MATTHEW · CIK 0001195414 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 244,303 F1 · shares: On December 31, 2020, the Reporting Person was issued 11,673 shares of common stock par value $.0001 per share pursuant to the Issuer's Amended and Restated 2013 Equity Compensation Plan. Such shares vest immediately upon grant. Read SEC document |
| December 01, 2020 Filed Dec 3, 2020 21:08 UTC |
Liu HuiChief Technology Officer
|
GrantStock option (right to buy) · Derivative | 350,000 | $0.00 Strike: $1.07 | $0.00 |
DisclosureSEC source: 0001493152-20-022913 · ownership.xml · derivative · entry 1 Hui Liu · CIK 0001834660 · Chief Technology Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 350,000 Underlying: Common Stock · 350,000 shares Expires 2030-12-01 F1 · derivative.exercise_date: The option award was made in accordance with the terms of the Issuer's Amended and Restated 2013 Equity Incentive Plan (the "2013 Plan"). The option vests as to 25% on December 1, 2021, thereafter the remaining options vest in equal monthly installments over a period of 36 months commencing on January 1, 2022. Read SEC document |
| November 02, 2020 Filed Nov 10, 2020 16:05 UTC |
LEPORE PATRICK GDirector
|
GrantStock option (right to buy) · Derivative | 122,605 | $0.00 Strike: $0.82 | $0.00 |
DisclosureSEC source: 0001493152-20-020925 · ownership.xml · derivative · entry 1 LEPORE PATRICK G · CIK 0001055404 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 122,605 Underlying: Common Stock · 122,605 shares Expires 2030-11-02 F1 · derivative.exercise_date: The option award was made in accordance with the terms of the Issuer's Amended and Restated 2013 Equity Incentive Plan (the "2013 Plan"). The option vests in equal monthly installments over a period of 12 months commencing on December 1, 2020. The exercise price is based on the closing price for the shares of the Common Stock on the date of grant in accordance with the terms of the 2013 Plan. Read SEC document |
| November 02, 2020 Filed Nov 10, 2020 16:05 UTC |
Ende Eric JDirector
|
GrantStock option (right to buy) · Derivative | 122,605 | $0.00 Strike: $0.82 | $0.00 |
DisclosureSEC source: 0001493152-20-020922 · ownership.xml · derivative · entry 1 Ende Eric J · CIK 0001494386 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 122,605 Underlying: Common Stock · 122,605 shares Expires 2030-11-02 F1 · derivative.exercise_date: The option award was made in accordance with the terms of the Issuer's Amended and Restated 2013 Equity Incentive Plan (the "2013 Plan"). The option vests in equal monthly installments over a period of 12 months commencing on December 1, 2020. The exercise price is based on the closing price for the shares of the Common Stock on the date of grant in accordance with the terms of the 2013 Plan. Read SEC document |
| November 02, 2020 Filed Nov 10, 2020 16:05 UTC |
WIKLER MATTHEWDirector
|
GrantStock option (right to buy) · Derivative | 122,605 | $0.00 Strike: $0.82 | $0.00 |
DisclosureSEC source: 0001493152-20-020923 · ownership.xml · derivative · entry 1 WIKLER MATTHEW · CIK 0001195414 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 122,605 Underlying: Common Stock · 122,605 shares Expires 2030-11-02 F1 · derivative.exercise_date: The option award was made in accordance with the terms of the Issuer's Amended and Restated 2013 Equity Incentive Plan (the "2013 Plan"). The option vests in equal monthly installments over a period of 12 months commencing on December 1, 2020. The exercise price is based on the closing price for the shares of the Common Stock on the date of grant in accordance with the terms of the 2013 Plan. Read SEC document |
| November 02, 2020 Filed Nov 10, 2020 21:05 UTC |
CONRAD HERBERT JDirector
|
GrantStock option (right to buy) · Derivative | 122,605 | $0.00 Strike: $0.82 | $0.00 |
DisclosureSEC source: 0001493152-20-020921 · ownership.xml · derivative · entry 1 CONRAD HERBERT J · CIK 0001218815 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 122,605 Underlying: Common Stock · 122,605 shares Expires 2030-11-02 F1 · derivative.exercise_date: The option award was made in accordance with the terms of the Issuer's Amended and Restated 2013 Equity Incentive Plan (the "2013 Plan"). The option vests in equal monthly installments over a period of 12 months commencing on December 1, 2020. The exercise price is based on the closing price for the shares of the Common Stock on the date of grant in accordance with the terms of the 2013 Plan. Read SEC document |
| November 02, 2020 Filed Nov 10, 2020 16:05 UTC |
Scibetta James SDirector
|
GrantStock option (right to buy) · Derivative | 122,605 | $0.00 Strike: $0.82 | $0.00 |
DisclosureSEC source: 0001493152-20-020924 · ownership.xml · derivative · entry 1 Scibetta James S · CIK 0001383242 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 122,605 Underlying: Common Stock · 122,605 shares Expires 2030-11-02 F1 · derivative.exercise_date: The option award was made in accordance with the terms of the Issuer's Amended and Restated 2013 Equity Incentive Plan (the "2013 Plan"). The option vests in equal monthly installments over a period of 12 months commencing on December 1, 2020. The exercise price is based on the closing price for the shares of the Common Stock on the date of grant in accordance with the terms of the 2013 Plan. Read SEC document |
| September 30, 2020 Filed Oct 6, 2020 16:05 UTC |
WIKLER MATTHEWDirector
|
GrantCommon Stock | 20,725 | $0.00 | $0.00 |
DisclosureSEC source: 0001493152-20-019017 · ownership.xml · nonDerivative · entry 1 WIKLER MATTHEW · CIK 0001195414 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 232,630 F1 · shares: On September 30, 2020, the Reporting Person was issued 20,725 shares of common stock par value $.0001 per share pursuant to the Issuer's Amended and Restated 2013 Equity Compensation Plan. Such shares vest immediately upon grant. Read SEC document |
| August 21, 2020 Filed Aug 24, 2020 14:00 UTC |
STERN ADAM KDirector
|
PurchaseCommon Stock, par value $0.0001 per share | 20,000 | $0.83 | $16,600.00 |
DisclosureSEC source: 0001493152-20-016580 · ownership.xml · nonDerivative · entry 1 STERN ADAM K · CIK 0001403497 · Director 10b5-1 filing: Not disclosed Ownership: Indirect · Held by AKS Family Partners LP Disclosed balance after: 3,301,983 F1 · ownership.nature: Mr. Stern disclaims beneficial ownership of these securities except to the extent of his pecuniary interest therein, if any, and the inclusion of these securities in this report shall not be deemed an admission of beneficial ownership by Mr. Stern of the reported securities for purposes of Section 16 or any other purpose. Read SEC document |
| June 30, 2020 Filed Jul 2, 2020 20:45 UTC |
WIKLER MATTHEWDirector
|
GrantCommon Stock | 20,537 | $0.00 | $0.00 |
DisclosureSEC source: 0001493152-20-012586 · ownership.xml · nonDerivative · entry 1 WIKLER MATTHEW · CIK 0001195414 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 211,905 F1 · shares: On June 30, 2020, the Reporting Person was issued 20,537 shares of common stock par value $.0001 per share pursuant to the Issuer's Amended and Restated 2013 Equity Compensation Plan. Such shares vest immediately upon grant. Read SEC document |
| June 23, 2020 Filed Jun 24, 2020 21:00 UTC |
Ende Eric JDirector
|
OtherCommon Stock, par value $0.0001 per share | 3,600 | $0.00 | $0.00 |
DisclosureSEC source: 0001493152-20-011761 · ownership.xml · nonDerivative · entry 1 Ende Eric J · CIK 0001494386 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 115,292 F1 · kind: Stock dividend, payable to all holders of record of Series B Preferred Stock of 300 shares of Common Stock for each share of Series B Preferred Stock. Read SEC document |
| June 23, 2020 Filed Jun 25, 2020 01:00 UTC |
STERN ADAM KDirector
|
OtherCommon Stock, par value $0.0001 per share | 25,500 | $0.00 | $0.00 |
DisclosureSEC source: 0001493152-20-011758 · ownership.xml · nonDerivative · entry 1 STERN ADAM K · CIK 0001403497 · Director 10b5-1 filing: Not disclosed Ownership: Indirect · Held by AKS Family Partners LP Disclosed balance after: 3,281,983 F1 · kind: Stock dividend, payable to all holders of record of Series B Preferred Stock of 300 shares of Common Stock for each share of Series B Preferred Stock. F2 · ownership.nature: Mr. Stern disclaims beneficial ownership of these securities except to the extent of his pecuniary interest therein, if any, and the inclusion of these securities in this report shall not be deemed an admission of beneficial ownership by Mr. Stern of the reported securities for purposes of Section 16 or any other purpose. Read SEC document |
| June 23, 2020 Filed Jun 24, 2020 21:00 UTC |
WIKLER MATTHEWDirector
|
OtherCommon Stock, par value $0.0001 per share | 1,800 | $0.00 | $0.00 |
DisclosureSEC source: 0001493152-20-011762 · ownership.xml · nonDerivative · entry 1 WIKLER MATTHEW · CIK 0001195414 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 191,368 F1 · kind: Stock dividend, payable to all holders of record of Series B Preferred Stock of 300 shares of Common Stock for each share of Series B Preferred Stock. Read SEC document |
| June 23, 2020 Filed Jun 24, 2020 21:00 UTC |
MANNINO RAPHAEL JChief Scientific Officer
|
OtherCommon Stock, par value $0.0001 per share | 3,000 | $0.00 | $0.00 |
DisclosureSEC source: 0001493152-20-011760 · ownership.xml · nonDerivative · entry 1 MANNINO RAPHAEL J · CIK 0001196697 · Chief Scientific Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 1,429,565 F1 · kind: Stock dividend, payable to all holders of record of Series B Preferred Stock of 300 shares of Common Stock for each share of Series B Preferred Stock. Read SEC document |
| June 23, 2020 Filed Jun 25, 2020 01:00 UTC |
CONRAD HERBERT JDirector
|
OtherCommon Stock, par value $0.0001 per share | 30,000 | $0.00 | $0.00 |
DisclosureSEC source: 0001493152-20-011764 · ownership.xml · nonDerivative · entry 1 CONRAD HERBERT J · CIK 0001218815 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 544,622 F1 · kind: Stock dividend, payable to all holders of record of Series B Preferred Stock of 300 shares of Common Stock for each share of Series B Preferred Stock. Read SEC document |
| June 23, 2020 Filed Jun 24, 2020 21:00 UTC |
Scibetta James SDirector
|
OtherCommon Stock, par value $0.0001 per share | 3,600 | $0.00 | $0.00 |
DisclosureSEC source: 0001493152-20-011759 · ownership.xml · nonDerivative · entry 1 Scibetta James S · CIK 0001383242 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 621,158 F1 · kind: Stock dividend, payable to all holders of record of Series B Preferred Stock of 300 shares of Common Stock for each share of Series B Preferred Stock. Read SEC document |
| June 23, 2020 Filed Jun 25, 2020 01:00 UTC |
Jabbour Jerome DDirector · President and CEO
|
OtherCommon Stock, par value $0.0001 per share | 4,500 | $0.00 | $0.00 |
DisclosureSEC source: 0001493152-20-011763 · ownership.xml · nonDerivative · entry 1 Jabbour Jerome D · CIK 0001698838 · Director · President and CEO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 804,011 F1 · kind: Stock dividend, payable to all holders of record of Series B Preferred Stock of 300 shares of Common Stock for each share of Series B Preferred Stock. Read SEC document |
| June 17, 2020 Filed Jun 19, 2020 17:30 UTC |
MANNINO RAPHAEL JChief Scientific Officer
|
GrantStock option (right to buy) · Derivative | 50,000 | $0.00 Strike: $0.82 | $0.00 |
DisclosureSEC source: 0001493152-20-011534 · ownership.xml · derivative · entry 1 MANNINO RAPHAEL J · CIK 0001196697 · Chief Scientific Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 50,000 Underlying: Common Stock · 50,000 shares Expires 2030-06-16 F1 · derivative.exercise_date: The option award was made in accordance with the terms of the Issuer's Amended and Restated 2013 Equity Incentive Plan. Vesting is performance based and tied to achievement of positive topline ENHANCE-IT data (the "Milestone"). The option vests as to 1/3 upon achievement of the Milestone, with the remaining options to vest 1/3 on the first anniversary of such Milestone and 1/3 on the second anniversary of such Milestone. Read SEC document |
| June 17, 2020 Filed Jun 19, 2020 21:30 UTC |
Jabbour Jerome DDirector · President and CEO
|
GrantStock option (right to buy) · Derivative | 500,000 | $0.00 Strike: $0.82 | $0.00 |
DisclosureSEC source: 0001493152-20-011536 · ownership.xml · derivative · entry 1 Jabbour Jerome D · CIK 0001698838 · Director · President and CEO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 500,000 Underlying: Common Stock · 500,000 shares Expires 2030-06-16 F1 · derivative.exercise_date: The option award was made in accordance with the terms of the Issuer's Amended and Restated 2013 Equity Incentive Plan. Vesting is performance based and tied to achievement of positive topline ENHANCE-IT data (the "Milestone"). The option vests as to 1/3 upon achievement of the Milestone, with the remaining options to vest 1/3 on the first anniversary of such Milestone and 1/3 on the second anniversary of such Milestone. Read SEC document |
| June 17, 2020 Filed Jun 19, 2020 21:30 UTC |
Matkovits TheresaChief Development Officer
|
GrantStock option (right to buy) · Derivative | 175,000 | $0.00 Strike: $0.82 | $0.00 |
DisclosureSEC source: 0001493152-20-011535 · ownership.xml · derivative · entry 1 Matkovits Theresa · CIK 0001745393 · Chief Development Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 175,000 Underlying: Common Stock · 175,000 shares Expires 2030-06-16 F1 · derivative.exercise_date: The option award was made in accordance with the terms of the Issuer's Amended and Restated 2013 Equity Incentive Plan. Vesting is performance based and tied to achievement of positive topline ENHANCE-IT data (the "Milestone"). The option vests as to 1/3 upon achievement of the Milestone, with the remaining options to vest 1/3 on the first anniversary of such Milestone and 1/3 on the second anniversary of such Milestone. Read SEC document |
| June 17, 2020 Filed Jun 19, 2020 21:30 UTC |
Kucinski Keith AChief Financial Officer
|
GrantStock option (right to buy) · Derivative | 175,000 | $0.00 Strike: $0.82 | $0.00 |
DisclosureSEC source: 0001493152-20-011533 · ownership.xml · derivative · entry 1 Kucinski Keith A · CIK 0001763405 · Chief Financial Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 175,000 Underlying: Common Stock · 175,000 shares Expires 2030-06-16 F1 · derivative.exercise_date: The option award was made in accordance with the terms of the Issuer's Amended and Restated 2013 Equity Incentive Plan. Vesting is performance based and tied to achievement of positive topline ENHANCE-IT data (the "Milestone"). The option vests as to 1/3 upon achievement of the Milestone, with the remaining options to vest 1/3 on the first anniversary of such Milestone and 1/3 on the second anniversary of such Milestone. Read SEC document |
| June 17, 2020 Filed Jun 19, 2020 21:30 UTC |
Ferguson James J. IIIChief Medical Officer
|
GrantStock option (right to buy) · Derivative | 250,000 | $0.00 Strike: $0.82 | $0.00 |
DisclosureSEC source: 0001493152-20-011532 · ownership.xml · derivative · entry 1 Ferguson James J. III · CIK 0001769041 · Chief Medical Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 250,000 Underlying: Common Stock · 250,000 shares Expires 2030-06-16 F1 · derivative.exercise_date: The option award was made in accordance with the terms of the Issuer's Amended and Restated 2013 Equity Incentive Plan. Vesting is performance based and tied to achievement of positive topline ENHANCE-IT data (the "Milestone"). The option vests as to 1/3 upon achievement of the Milestone, with the remaining options to vest 1/3 on the first anniversary of such Milestone and 1/3 on the second anniversary of such Milestone. Read SEC document |
| June 04, 2020 Filed Jun 5, 2020 20:10 UTC |
CONRAD HERBERT JDirector
|
GiftCommon Stock, par value $0.0001 per share | 2,639,039 | $0.00 | $0.00 |
DisclosureSEC source: 0001493152-20-010651 · ownership.xml · nonDerivative · entry 2 CONRAD HERBERT J · CIK 0001218815 · Director 10b5-1 filing: Not disclosed Ownership: Indirect · By Herbert Conrad 2020 Grantor Retained Annuity Trust (GRAT) Disclosed balance after: 2,639,039 Read SEC document |
| June 04, 2020 Filed Jun 5, 2020 20:10 UTC |
CONRAD HERBERT JDirector
|
GiftCommon Stock, par value $0.0001 per share | 2,639,039 | $0.00 | $0.00 |
DisclosureSEC source: 0001493152-20-010651 · ownership.xml · nonDerivative · entry 1 CONRAD HERBERT J · CIK 0001218815 · Director 10b5-1 filing: Not disclosed Ownership: Indirect · By Herbert J. Conrad Trust u/a/d 3/4/2005, Herbert J Conrad and Judith Conrad, Trustees Disclosed balance after: 125,000 Read SEC document |
| May 14, 2020 Filed May 18, 2020 10:00 UTC |
LEPORE PATRICK GDirector
|
PurchaseCommon Stock, par value $0.0001 per share | 100,000 | $0.73 | $73,050.00 |
DisclosureSEC source: 0001493152-20-009278 · ownership.xml · nonDerivative · entry 1 LEPORE PATRICK G · CIK 0001055404 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 400,000 F1 · price: The price represents the weighted average purchase price for multiple transactions reported on this line. The prices of the transactions ranged from $0.7248 to $0.7399, inclusive. The reporting person undertakes to provide to Matinas BioPharma Holdings, Inc., any security holder of Matinas BioPharma Holdings, Inc., or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares acquired at each separate price within the ranges set forth herein. Read SEC document |
| May 13, 2020 Filed May 15, 2020 20:01 UTC |
CONRAD HERBERT JDirector
|
GiftCommon Stock, par value $0.0001 per share | 2,639,039 | $0.00 | $0.00 |
DisclosureSEC source: 0001493152-20-009089 · ownership.xml · nonDerivative · entry 2 CONRAD HERBERT J · CIK 0001218815 · Director 10b5-1 filing: Not disclosed Ownership: Indirect · By Herbert J. Conrad Trust u/a/d 3/4/2005, Herbert J Conrad and Judith Conrad, Trustees Disclosed balance after: 2,764,039 Read SEC document |
| May 13, 2020 Filed May 15, 2020 20:01 UTC |
CONRAD HERBERT JDirector
|
GiftCommon Stock, par value $0.0001 per share | 2,639,039 | $0.00 | $0.00 |
DisclosureSEC source: 0001493152-20-009089 · ownership.xml · nonDerivative · entry 1 CONRAD HERBERT J · CIK 0001218815 · Director 10b5-1 filing: Not disclosed Ownership: Indirect · By Herbert Conrad 2019 Grantor Retained Annuity Trust (GRAT) Disclosed balance after: 1,145,905 Read SEC document |
| April 03, 2020 Filed Apr 8, 2020 20:38 UTC |
STERN ADAM KDirector
|
Exercise / conversionWarrant (right to buy) · Derivative | 952,676 | $0.00 Strike: $0.50 | $0.00 |
DisclosureSEC source: 0001493152-20-006066 · ownership.xml · derivative · entry 8 STERN ADAM K · CIK 0001403497 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 0 Underlying: Common Stock · 952,676 shares Expires 2020-04-09 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. Read SEC document |
| April 03, 2020 Filed Apr 8, 2020 20:38 UTC |
STERN ADAM KDirector
|
Exercise / conversionCommon Stock, par value $0.0001 per share | 278,407 | $0.50 | $139,203.50 |
DisclosureSEC source: 0001493152-20-006066 · ownership.xml · nonDerivative · entry 1 STERN ADAM K · CIK 0001403497 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 1,337,399 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · kind: On April 3, 2020, the reporting person exercised a warrant to purchase 952,676 shares of Matinas BioPharma Holdings, Inc. common stock for $0.50 a share. The reporting person paid the exercise price on a cashless basis, resulting in Matinas BioPharma Holdings, Inc.'s withholding of 674,269 of the warrant shares to pay the exercise price and issuing to the reporting person the remaining 278,407 shares. The value of the shares cancelled was $0.7065 per share, which represents the average closing price of the shares for the 20 trading days immediately preceding the date of exercise. Read SEC document |
| March 31, 2020 Filed Apr 2, 2020 16:10 UTC |
WIKLER MATTHEWDirector
|
GrantCommon Stock | 26,450 | $0.00 | $0.00 |
DisclosureSEC source: 0001493152-20-005693 · ownership.xml · nonDerivative · entry 1 WIKLER MATTHEW · CIK 0001195414 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 189,568 F1 · shares: On March 31, 2020, the Reporting Person was issued 26,450 shares of common stock par value $.0001 per share pursuant to the Issuer's Amended and Restated 2013 Equity Compensation Plan. Such shares vest immediately upon grant. Read SEC document |
| March 17, 2020 Filed Mar 18, 2020 14:51 UTC |
STERN ADAM KDirector
|
PurchaseCommon Stock, par value $0.0001 per share | 10,000 | $0.65 | $6,500.00 |
DisclosureSEC source: 0001493152-20-004196 · ownership.xml · nonDerivative · entry 1 STERN ADAM K · CIK 0001403497 · Director 10b5-1 filing: Not disclosed Ownership: Indirect · Held by SternAegis Ventures, LLC 401(k) Profit Sharing Plan Disclosed balance after: 10,000 F2 · price: The price represents the weighted average purchase price for multiple transactions reported on this line. The prices of the transactions ranged from $0.64 to $0.65, inclusive. The reporting person undertakes to provide to Matinas BioPharma Holdings, Inc., any security holder of Matinas BioPharma Holdings, Inc., or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the ranges set forth herein. F1 · ownership.nature: Mr. Stern disclaims beneficial ownership of these securities except to the extent of his pecuniary interest therein, if any, and the inclusion of these securities in this report shall not be deemed an admission of beneficial ownership by Mr. Stern of the reported securities for purposes of Section 16 or any other purpose. Read SEC document |
| March 17, 2020 Filed Mar 18, 2020 14:50 UTC |
Jabbour Jerome DDirector · President and CEO
|
PurchaseCommon Stock, par value $0.0001 per share | 10,000 | $0.65 | $6,500.00 |
DisclosureSEC source: 0001493152-20-004195 · ownership.xml · nonDerivative · entry 1 Jabbour Jerome D · CIK 0001698838 · Director · President and CEO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 799,511 F1 · price: The price represents the weighted average purchase price for multiple transactions reported on this line. The prices of the transactions ranged from $0.64 to $0.65, inclusive. The reporting person undertakes to provide to Matinas BioPharma Holdings, Inc., any security holder of Matinas BioPharma Holdings, Inc., or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the ranges set forth herein. Read SEC document |
| January 01, 2020 Filed Jan 3, 2020 16:06 UTC |
MANNINO RAPHAEL JChief Scientific Officer
|
GrantStock option (right to buy) · Derivative | 100,000 | $0.00 Strike: $2.27 | $0.00 |
DisclosureSEC source: 0001493152-20-000125 · ownership.xml · derivative · entry 2 MANNINO RAPHAEL J · CIK 0001196697 · Chief Scientific Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 100,000 Underlying: Common Stock · 100,000 shares Expires 2030-01-01 F2 · derivative.exercise_date: The option award was made in accordance with the terms of the Issuer's Amended and Restated 2013 Equity Incentive Plan. The option vests as to 25% of the shares on January 1, 2021 with the remaining shares to vest in equal monthly installments over a period of 36 months commencing on February 1, 2021. Read SEC document |
| January 01, 2020 Filed Jan 3, 2020 21:05 UTC |
Kucinski Keith AChief Financial Officer
|
GrantStock option (right to buy) · Derivative | 350,000 | $0.00 Strike: $2.27 | $0.00 |
DisclosureSEC source: 0001493152-20-000124 · ownership.xml · derivative · entry 1 Kucinski Keith A · CIK 0001763405 · Chief Financial Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 350,000 Underlying: Common Stock · 350,000 shares Expires 2030-01-01 F1 · derivative.exercise_date: The option award was made in accordance with the terms of the Issuer's Amended and Restated 2013 Equity Incentive Plan. The option vests as to 25% of the shares on January 1, 2021 with the remaining shares to vest in equal monthly installments over a period of 36 months commencing on February 1, 2021. Read SEC document |
| January 01, 2020 Filed Jan 3, 2020 21:05 UTC |
Ferguson James J. IIIChief Medical Officer
|
GrantStock option (right to buy) · Derivative | 500,000 | $0.00 Strike: $2.27 | $0.00 |
DisclosureSEC source: 0001493152-20-000120 · ownership.xml · derivative · entry 1 Ferguson James J. III · CIK 0001769041 · Chief Medical Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 500,000 Underlying: Common Stock · 500,000 shares Expires 2030-01-01 F1 · derivative.exercise_date: The option award was made in accordance with the terms of the Issuer's Amended and Restated 2013 Equity Incentive Plan. The option vests as to 25% of the shares on January 1, 2021 with the remaining shares to vest in equal monthly installments over a period of 36 months commencing on February 1, 2021. Read SEC document |
| January 01, 2020 Filed Jan 3, 2020 21:05 UTC |
Matkovits TheresaChief Development Officer
|
GrantStock option (right to buy) · Derivative | 350,000 | $0.00 Strike: $2.27 | $0.00 |
DisclosureSEC source: 0001493152-20-000118 · ownership.xml · derivative · entry 1 Matkovits Theresa · CIK 0001745393 · Chief Development Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 350,000 Underlying: Common Stock · 350,000 shares Expires 2030-01-01 F1 · derivative.exercise_date: The option award was made in accordance with the terms of the Issuer's Amended and Restated 2013 Equity Incentive Plan. The option vests as to 25% of the shares on January 1, 2021 with the remaining shares to vest in equal monthly installments over a period of 36 months commencing on February 1, 2021. Read SEC document |
| January 01, 2020 Filed Jan 3, 2020 21:05 UTC |
Jabbour Jerome DDirector · President and CEO
|
GrantStock option (right to buy) · Derivative | 1,000,000 | $0.00 Strike: $2.27 | $0.00 |
DisclosureSEC source: 0001493152-20-000116 · ownership.xml · derivative · entry 2 Jabbour Jerome D · CIK 0001698838 · Director · President and CEO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 1,000,000 Underlying: Common Stock · 1,000,000 shares Expires 2030-01-01 F2 · derivative.exercise_date: The option award was made in accordance with the terms of the Issuer's Amended and Restated 2013 Equity Incentive Plan. The option vests as to 25% of the shares on January 1, 2021 with the remaining shares to vest in equal monthly installments over a period of 36 months commencing on February 1, 2021. Read SEC document |
| December 31, 2019 Filed Jan 3, 2020 21:05 UTC |
CONRAD HERBERT JDirector
|
GrantCommon Stock, par value $0.0001 per share | 10,573 | $0.00 | $0.00 |
DisclosureSEC source: 0001493152-20-000123 · ownership.xml · nonDerivative · entry 1 CONRAD HERBERT J · CIK 0001218815 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 514,622 F1 · shares: On December 31, 2019, the Reporting Person was issued 10,573 shares of common stock par value $.0001 per share pursuant to the Issuer's Amended and Restated 2013 Equity Incentive Plan. Such shares vest immediately upon grant. Read SEC document |
| December 31, 2019 Filed Jan 3, 2020 16:05 UTC |
WIKLER MATTHEWDirector
|
GrantCommon Stock, par value $0.0001 per share | 6,994 | $0.00 | $0.00 |
DisclosureSEC source: 0001493152-20-000117 · ownership.xml · nonDerivative · entry 1 WIKLER MATTHEW · CIK 0001195414 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 163,118 F1 · shares: On December 31, 2019, the Reporting Person was issued 6,994 shares of common stock par value $.0001 per share pursuant to the Issuer's Amended and Restated 2013 Equity Incentive Plan. Such shares vest immediately upon grant. Read SEC document |
| December 31, 2019 Filed Jan 3, 2020 16:06 UTC |
Scibetta James SDirector
|
GrantCommon Stock, par value $0.0001 per share | 8,260 | $0.00 | $0.00 |
DisclosureSEC source: 0001493152-20-000126 · ownership.xml · nonDerivative · entry 1 Scibetta James S · CIK 0001383242 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 617,558 F1 · shares: On December 31, 2019, the Reporting Person was issued 8,260 shares of common stock par value $.0001 per share pursuant to the Issuer's Amended and Restated 2013 Equity Incentive Plan. Such shares vest immediately upon grant. Read SEC document |
| November 25, 2019 Filed Nov 26, 2019 15:00 UTC |
Kucinski Keith AChief Financial Officer
|
PurchaseCommon Stock, par value $0.0001 per share | 58,000 | $1.23 | $71,160.20 |
DisclosureSEC source: 0001493152-19-018412 · ownership.xml · nonDerivative · entry 2 Kucinski Keith A · CIK 0001763405 · Chief Financial Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 94,500 Read SEC document |
| November 22, 2019 Filed Nov 26, 2019 15:00 UTC |
Kucinski Keith AChief Financial Officer
|
PurchaseCommon Stock, par value $0.0001 per share | 36,500 | $1.20 | $43,807.30 |
DisclosureSEC source: 0001493152-19-018412 · ownership.xml · nonDerivative · entry 1 Kucinski Keith A · CIK 0001763405 · Chief Financial Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 36,500 F1 · price: The price represents the weighted average purchase price for multiple transactions reported on this line. The prices of the transactions ranged from $1.17 to $1.23, inclusive. The reporting person undertakes to provide to Matinas BioPharma Holdings, Inc., any security holder of Matinas BioPharma Holdings, Inc., or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the ranges set forth herein. Read SEC document |
| November 15, 2019 Filed Nov 19, 2019 10:00 UTC |
LEPORE PATRICK GDirector
|
PurchaseCommon Stock, par value $0.0001 per share | 100,000 | $1.06 | $105,530.00 |
DisclosureSEC source: 0001493152-19-017920 · ownership.xml · nonDerivative · entry 1 LEPORE PATRICK G · CIK 0001055404 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 300,000 Read SEC document |
| November 01, 2019 Filed Nov 5, 2019 16:05 UTC |
LEPORE PATRICK GDirector
|
GrantStock option (right to buy) · Derivative | 107,416 | $0.00 Strike: $0.91 | $0.00 |
DisclosureSEC source: 0001493152-19-016458 · ownership.xml · derivative · entry 1 LEPORE PATRICK G · CIK 0001055404 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 107,416 Underlying: Common Stock · 107,416 shares Expires 2029-11-01 F1 · derivative.exercise_date: The option award was made in accordance with the terms of the Issuer's Amended and Restated 2013 Equity Incentive Plan (the "2013 Plan"). The option vests in equal monthly installments over a period of 12 months commencing on December 1, 2019. The exercise price is based on the closing price for the shares of the Common Stock on the date of grant in accordance with the terms of the 2013 Plan. Read SEC document |
| November 01, 2019 Filed Nov 5, 2019 16:05 UTC |
Ende Eric JDirector
|
GrantStock option (right to buy) · Derivative | 107,416 | $0.00 Strike: $0.91 | $0.00 |
DisclosureSEC source: 0001493152-19-016453 · ownership.xml · derivative · entry 2 Ende Eric J · CIK 0001494386 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 107,416 Underlying: Common Stock · 107,416 shares Expires 2029-11-01 F2 · derivative.exercise_date: The option award was made in accordance with the terms of the Issuer's Amended and Restated 2013 Equity Incentive Plan (the "2013 Plan"). The option vests in equal monthly installments over a period of 12 months commencing on December 1, 2019. The exercise price is based on the closing price for the shares of the Common Stock on the date of grant in accordance with the terms of the 2013 Plan. Read SEC document |
| November 01, 2019 Filed Nov 5, 2019 21:05 UTC |
STERN ADAM KDirector
|
GrantStock option (right to buy) · Derivative | 107,416 | $0.00 Strike: $0.91 | $0.00 |
DisclosureSEC source: 0001493152-19-016457 · ownership.xml · derivative · entry 1 STERN ADAM K · CIK 0001403497 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 107,416 Underlying: Common Stock · 107,416 shares Expires 2029-11-01 F1 · derivative.exercise_date: The option award was made in accordance with the terms of the Issuer's Amended and Restated 2013 Equity Incentive Plan (the "2013 Plan"). The option vests in equal monthly installments over a period of 12 months commencing on December 1, 2019. The exercise price is based on the closing price for the shares of the Common Stock on the date of grant in accordance with the terms of the 2013 Plan. Read SEC document |
| November 01, 2019 Filed Nov 5, 2019 16:05 UTC |
WIKLER MATTHEWDirector
|
GrantStock option (right to buy) · Derivative | 107,416 | $0.00 Strike: $0.91 | $0.00 |
DisclosureSEC source: 0001493152-19-016454 · ownership.xml · derivative · entry 1 WIKLER MATTHEW · CIK 0001195414 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 107,416 Underlying: Common Stock · 107,416 shares Expires 2029-11-01 F1 · derivative.exercise_date: The option award was made in accordance with the terms of the Issuer's Amended and Restated 2013 Equity Incentive Plan (the "2013 Plan"). The option vests in equal monthly installments over a period of 12 months commencing on December 1, 2019. The exercise price is based on the closing price for the shares of the Common Stock on the date of grant in accordance with the terms of the 2013 Plan. Read SEC document |
| November 01, 2019 Filed Nov 5, 2019 21:05 UTC |
CONRAD HERBERT JDirector
|
GrantStock option (right to buy) · Derivative | 107,416 | $0.00 Strike: $0.91 | $0.00 |
DisclosureSEC source: 0001493152-19-016456 · ownership.xml · derivative · entry 1 CONRAD HERBERT J · CIK 0001218815 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 107,416 Underlying: Common Stock · 107,416 shares Expires 2029-11-01 F1 · derivative.exercise_date: The option award was made in accordance with the terms of the Issuer's Amended and Restated 2013 Equity Incentive Plan (the "2013 Plan"). The option vests in equal monthly installments over a period of 12 months commencing on December 1, 2019. The exercise price is based on the closing price for the shares of the Common Stock on the date of grant in accordance with the terms of the 2013 Plan. Read SEC document |
Value uses the disclosed total when available, otherwise shares × reported transaction price. It is not an estimate of exercise cash cost or investment performance.